The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1737
September 15, 2025
View Complete Issue         Table of Contents 2019 
Ceftobiprole Medocaril (Zevtera) — A New Cephalosporin Antibiotic
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Ceftobiprole Medocaril (Zevtera) — A New Cephalosporin Antibiotic
September 15, 2025 (Issue: 1737)
Ceftobiprole medocaril sodium (Zevtera – Innoviva Specialty Therapeutics), a new IV cephalosporin antibacterial drug, has been approved by the FDA for treatment of Staphylococcus aureus bacteremia (SAB), including right-sided infective...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Ceftobiprole Medocaril (Zevtera) — A New Cephalosporin Antibiotic
Article code: 1737d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.